Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? 1996

G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
Department of Urology, Erasme Hospital, University Clinics of Brussels, Brussels, Belgium.

BACKGROUND Prostatic intraepithelial neoplasia (PIN) is considered to be a precursor of prostate carcinoma in which serum levels of prostate specific antigen (PSA) have been correlated with PIN grades. The aim of this study was to determine whether PSA and prostate specific antigen density (PSAD), obtained at the time of initial diagnosis of PIN without concurrent carcinoma, can be used as predictive factors to discriminate patients with subsequent cancer on repeat biopsy. METHODS We studied, retrospectively, the records of 93 patients with PIN (low and high grade) without concurrent carcinoma at the time of their first needle biopsy. We assessed the relationship between initial PIN grade, PSA, and PSAD with later detection of carcinoma on repeat biopsy. Patients were divided into 3 subgroups for analysis according to their initial PSA level (0-4, 4.1-10, >10 ng/mL). RESULTS Carcinoma detection rate on repeat biopsy was 13.3% for patients with low grade PIN and 47.7% for patients with high grade PIN (P < 0.006). High grade PIN was frequently associated with subsequent carcinoma whatever the PSA level (33.3-61.9%). Low grade PIN was associated with subsequent carcinoma in 42.8% of the cases when PSA was greater than 10 ng/mL. When PSA was between 4 and 10 ng/mL, low grade PIN carcinoma was found on repeat biopsies in only 10.7% of the cases (P = 0.05). In none of the PSA subgroups did PSAD enhance later cancer detection. CONCLUSIONS For patients with high grade PIN, the incidence of subsequent carcinoma is high, whatever the PSA values. For these cases repeat biopsies should be recommended. Patients with low grade PIN and PSA greater than 10 ng/mL should have repeat biopsies because the incidence of subsequent carcinoma is high and comparable to high grade PIN. PSAD did not provide additional information.

UI MeSH Term Description Entries
D008297 Male Males
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001707 Biopsy, Needle Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed. Aspiration Biopsy,Puncture Biopsy,Aspiration Biopsies,Biopsies, Aspiration,Biopsies, Needle,Biopsies, Puncture,Biopsy, Aspiration,Biopsy, Puncture,Needle Biopsies,Needle Biopsy,Puncture Biopsies
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein
D019048 Prostatic Intraepithelial Neoplasia A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer. Neoplasia, Prostatic Intraepithelial,Intraepithelial Prostatic Neoplasia,Prostatic Intraepithelial Neoplasms,Intraepithelial Neoplasia, Prostatic,Intraepithelial Neoplasm, Prostatic,Intraepithelial Neoplasms, Prostatic,Intraepithelial Prostatic Neoplasias,Neoplasia, Intraepithelial Prostatic,Neoplasm, Prostatic Intraepithelial,Neoplasms, Prostatic Intraepithelial,Prostatic Intraepithelial Neoplasias,Prostatic Intraepithelial Neoplasm,Prostatic Neoplasia, Intraepithelial

Related Publications

G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
January 1993, World journal of urology,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
December 1989, Urology,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
December 1989, Urology,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
July 2004, Histology and histopathology,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
December 2015, The Canadian journal of urology,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
January 1995, Urologic oncology,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
September 1997, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
January 2002, Scandinavian journal of urology and nephrology,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
May 1996, Urology,
G Raviv, and A R Zlotta, and T h Janssen, and F Descamps, and J P Vanegas, and A Verhest, and C C Schulman
September 2012, European urology,
Copied contents to your clipboard!